Tasly Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate
Tasly Pharmaceutical Group Co Ltd cash flow reinvestment rate. Tasly Pharmaceutical Group Co Ltd (600535) has a Cash Flow Reinvestment Rate of 1.06x as of December 2025, reinvesting CN¥587.23 Million (capex CN¥117.78 Million plus investments CN¥-469.45 Million) from operating cash flow of CN¥552.13 Million. Explore cash flow to debt ratio of Tasly Pharmaceutical Group Co Ltd to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Tasly Pharmaceutical Group Co Ltd (2001–2025)
Cash flow reinvestment rate of Tasly Pharmaceutical Group Co Ltd from 2001 to 2025. Historical reinvestment intensity for Tasly Pharmaceutical Group Co Ltd across 24 annual periods. Explore Tasly Pharmaceutical Group Co Ltd capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Tasly Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate by Year (2001–2025)
Tasly Pharmaceutical Group Co Ltd cash flow reinvestment rate by year from 2001 to 2025. Year-by-year capital reinvestment analysis for Tasly Pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see Tasly Pharmaceutical Group Co Ltd cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.52x | CN¥746.36 Million | CN¥1.42 Billion | CN¥381.26 Million | ▲ +31.0% |
| 2024 | 0.40x | CN¥805.29 Million | CN¥2.01 Billion | CN¥564.94 Million | ▼ -62.9% |
| 2023 | 1.08x | CN¥2.78 Billion | CN¥2.58 Billion | CN¥668.82 Million | ▲ +86.2% |
| 2022 | 0.58x | CN¥1.32 Billion | CN¥2.29 Billion | CN¥403.45 Million | ▲ +132.4% |
| 2021 | 0.25x | CN¥698.14 Million | CN¥2.80 Billion | CN¥571.73 Million | ▼ -0.4% |
| 2020 | 0.25x | CN¥448.14 Million | CN¥1.79 Billion | CN¥408.81 Million | ▼ -52.4% |
| 2019 | 0.53x | CN¥882.46 Million | CN¥1.68 Billion | CN¥730.78 Million | ▼ -5.5% |
| 2018 | 0.56x | CN¥830.62 Million | CN¥1.49 Billion | CN¥780.10 Million | ▼ -7.3% |
| 2016 | 0.60x | CN¥691.89 Million | CN¥1.15 Billion | CN¥524.68 Million | ▼ -81.7% |
| 2015 | 3.28x | CN¥1.12 Billion | CN¥340.00 Million | CN¥737.84 Million | ▲ +168.1% |
| 2014 | 1.22x | CN¥754.93 Million | CN¥616.76 Million | CN¥754.93 Million | ▼ -36.1% |
| 2013 | 1.92x | CN¥663.56 Million | CN¥346.17 Million | CN¥663.56 Million | ▲ +103.1% |
| 2012 | 0.94x | CN¥390.02 Million | CN¥413.31 Million | CN¥390.02 Million | ▼ -69.8% |
| 2011 | 3.13x | CN¥422.58 Million | CN¥135.14 Million | CN¥422.58 Million | ▲ +643.6% |
| 2010 | 0.42x | CN¥166.13 Million | CN¥395.05 Million | CN¥166.13 Million | ▲ +44.1% |
| 2009 | 0.29x | CN¥116.80 Million | CN¥400.39 Million | CN¥116.80 Million | ▼ -33.7% |
| 2008 | 0.44x | CN¥114.51 Million | CN¥260.21 Million | CN¥114.51 Million | ▼ -51.5% |
| 2007 | 0.91x | CN¥201.23 Million | CN¥221.55 Million | CN¥201.23 Million | ▼ -50.0% |
| 2006 | 1.82x | CN¥255.41 Million | CN¥140.56 Million | CN¥255.41 Million | ▲ +31.8% |
| 2005 | 1.38x | CN¥296.33 Million | CN¥214.90 Million | CN¥296.33 Million | ▼ -24.2% |
| 2004 | 1.82x | CN¥369.62 Million | CN¥203.27 Million | CN¥369.62 Million | ▼ -67.4% |
| 2003 | 5.57x | CN¥328.74 Million | CN¥59.00 Million | CN¥328.74 Million | ▲ +811.2% |
| 2002 | 0.61x | CN¥126.09 Million | CN¥206.22 Million | CN¥126.09 Million | ▼ -57.1% |
| 2001 | 1.42x | CN¥119.35 Million | CN¥83.77 Million | CN¥119.35 Million | — |